Search
Colestipol
go.drugbank.com/drugs/DB00375Approvedbe good candidates for using the agent owing to its physical effects on the gut. … results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaTiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawn[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763] … [A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification.
Almotriptan
go.drugbank.com/drugs/DB00918ApprovedIt works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms … Almotriptan does not prevent migraine attacks.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeNintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigationalNintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). … nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to
Duvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigational[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585] … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma
Cupric oxide
go.drugbank.com/drugs/DB11134ApprovedCupric oxide poses potential health and environmental concern due to toxic and mutagenic particles generating reactive oxygen species [A32656].
Peginterferon alfa-2a
go.drugbank.com/drugs/DB00008ApprovedInvestigationalPeginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. … Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Nirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigational[A262561] Nirogacestat was approved under the brand name OGSIVEO on November 27, 2023, by the FDA for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. … Desmoid tumors are typically characterized by aberrant activation in Notch signaling.
Oxymorphone
go.drugbank.com/drugs/DB01192ApprovedVet approvedOn June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation. … It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092).
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeNovobiocin
go.drugbank.com/drugs/DB01051ApprovedInvestigationalVet approvedWithdrawnIt has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase and blocks adenosine triphosphatase (ATPase) activity. … Martindale The Extra Pharmacopoeia, 30th ed, p189) Novobiocin sodium, a salt form of novobiocin, was initially approved in September 1964 and was indicated for the treatment of serious infections due to
Synonyms: N-{7-[(3-O-carbamoyl-6-deoxy-5-methyl-4-O-methyl-β-D-gulopyranosyl)oxy]-4-hydroxy-8-methyl-2-oxo-2H-chromen-3-yl}-4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamide